Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ATIR after haploidentical CD34-selected peripheral blood stem cell transplantation
2008-008198-73Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Feb 2009
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATIR101 in hematopoietic malignancies and multiple myeloma (MM), sponsored by Kiadis Pharma. Primary endpoints: Incidence of transplant-related mortality at 6 months and Incidence of transplant-related mortality at 12 months. Started Feb 2009; status: completed.
02
Drugs
ATIR101
03
Conditions
hematopoietic malignanciesmultiple myeloma (MM)
Beyond the preview
Go deeper on 2008-008198-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008198-73.